Industry News

Glenmark Pharmaceuticals Inc., USA (Glenmark) get final approval by the United States Food & Drug Administration (FDA) for calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 per cent of Leo Pharma A/S.  Glenmark strategy to start to shipping of calcipotriene cream, 0.005 per cent immediately.

Horizon Discovery Group plc, UK translational genomics company developing and supplying patient-relevant drug discovery and diagnostic research toolsand DefiniGEN Ltd, a leading provider of stem cell products and services, have entered into a collaboration to develop a range of unique, gene-engineered iPS (induced pluripotent stem)-based cell lines for use in research.

[adsense:336x280:8701650588]

Romaco Group,  a leading global supplier of processing and packaging equipment, will be present the first ever anti-counterfeit solution for blister packs at ACHEMA, Frankfurt/Main (Germany), from June 15 to 19, 2015. The new system was developed exclusively with its partner company NANO 4 U. The system can be incorporated into all blister machines equipped with coding stations and will be showcased at Achema in a Romaco Noack line 960. The blisters feature a NANO4U hologram stamp which can incorporate a hidden logo or code, as well as other covert and overt safety features.

Multiplicom N.V., develops, manufactures and commercializes molecular diagnostic assays, launched two kits-- the BRCA Hereditary Cancer MASTR Plus kit and the BRCA Tumor MASTR Plus kit, to screen hereditary breast and ovarian cancers. The BRCA Hereditary Cancer MASTR kit detects germline variants in 26 genes associated with hereditary cancers and the BRCA Tumor MASTR Plus is used for detection of variants in BRCA1 and BRCA2 in tumour biopsy material.

The US Food and Drug Administration (FDA) has granted orphan-drug designation to biopharmaceutical company MediciNova Inc.'s MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).

ILife Discoveries, genetics and genomics company has introduced a new gene test in India. This will help oncologists get a deeper insight into tumors. The new MammaPrint & Blueprint test is able to analyse molecular subtypes of the cancer, risk of recurrence of early stage cancer, thereby enabling medical oncologists to take informed decisions on the course of treatment. For millions of breast cancer patients in India, the twin technologies are advancements that can shed new light on whether treatment is possible without undergoing the harsh chemotherapy process.

Pharmatech Associates and InQui Capital of Hong Kong announced the Pharmatech Connect programme, a collaboration bringing development opportunities to early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide.

BioCision is a leading supplier of cell cryopreservation products, systems, and solutions announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), for development of a cell thawing solution based on BioCision’s proprietary ThawSTAR technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

Mylan N.V., a global pharmaceutical company,  launched guanfacine extended-release tablets, 1 mg, 2 mg, 3 mg, and 4 mg, which is the generic version of Shire's Intuniv tablets in US markets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.The company received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.